FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HIGH SUSANNA GATTI						2. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics, Inc.</u> [DYN]							(Ch	5. Relationship of Reporting (Check all applicable) Director Officer (give title			son(s) to Iss 10% Ov Other (s	vner
(Last) 1560 TR	(Last) (First) (Middle) 1560 TRAPELO ROAD					3. Date of Earliest Transaction (Month/Day/Year) 06/12/2024								below) below) Chief Operating Officer				
(Street) WALTH	AM M	ΙA	4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ine) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	State) (Zip)				Rule 10b5-1(c) Transaction Indication												
Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Ir												n or written	plan th	at is intended	l to			
		Tak	ole I - No	n-Deri	vativ	e Se	curit	ties Ac	quired	, Dis	sposed o	f, or Be	neficial	y Owned	l			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			Benefici Owned I	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)	on(s)		(Instr. 4)
Common Stock				06/12	06/12/2024				M		40,000	A	\$5.54	188	8,792		D	
Common Stock 06/12				2/2024	2024			S ⁽¹⁾		26,036	D	\$33.17	162,756		D			
Common Stock 06/12/				2/2024	2024			S ⁽¹⁾		13,964	D	\$33.7	148,792(4)			D		
		-	Table II								osed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	n Date,	d 4. Date, Transact Code (Ins		5. Number of		6. Date E Expiration (Month/I	on Da		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Number of Shares					
Stock option (right to buy)	\$5.54	06/12/2024			M			40,000	(5)		07/30/2030	Common Stock	40,000	\$0	100,48	36	D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$32.50 to \$33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of \$33.51 to \$34.04, inclusive.
- 4. Includes 134,629 unvested RSUs.
- 5. The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter.

/s/ Richard Scalzo, Attorney-in-06/13/2024 **Fact**

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.